Lexeo Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $236.33M
- P/E (TTM)
- –
- Dividend yield
- –
About Lexeo Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Lexeo Therapeutics is a clinical-stage genetic medicine company that develops gene therapies for cardiovascular diseases with underlying genetic causes. Its therapeutic pipeline includes LX2006, an adeno-associated virus gene therapy candidate that delivers a functional frataxin gene to treat Friedreich ataxia cardiomyopathy. Another primary candidate, LX2020, delivers a functional PKP2 gene to address arrhythmogenic cardiomyopathy caused by PKP2 mutations. The company also develops LX2021 to provide functional connexin 43 protein for inherited cardiac muscle disorders. Operating within the biotechnology and genetic medicine sector, the company focuses on serving patients suffering from serious hereditary heart conditions.
The company is headquartered in New York, New York, where it maintains principal executive offices. Its clinical-stage research and development activities operate primarily in the United States, where its product candidates undergo evaluation in clinical trials. Lexeo maintains exclusive worldwide development and commercialization rights across all of its therapeutic programs, which target patient populations in the United States and international markets.
Summary of the business section of Lexeo Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Lexeo Therapeutics, Inc.
- Headquarters
- New York, NY
- Address
- 345 Park Avenue South, Floor 6 10010
- Phone
- (212) 547-9879
- Website
- lexeotx.com
- Employees
- 59, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, New York, NY
Stock & identifiers
- Ticker
- LXEO
- Exchange
- Nasdaq
- IPO date
- Nov 6, 2023
- Shares outstanding
- 82M, Aug 10, 2026
- Public float
- $216.50M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1907108
- CUSIP
- 52886X107
- ISIN
- US52886X1072
- EIN
- 85-4012572
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Richard Nolan Townsend | Chief Executive Officer, Director | 376,778 |
| Narinder Pal Bhalla | Chief Medical Officer | 84,908 |
| Jose Manuel Otero | Chief Operating Officer | 138,288 |
| Louis Edward Tamayo | Chief Financial Officer | 92,907 |
| Jenny Robertson | Chief Legal Officer | 68,381 |
| Tai Sandi See | Chief Development Officer | 65,476 |
| Eric Adler | Chief Medical Officer | 72,646 |
| Kyle Rasbach | Chief Financial Officer | 40,875 |
| Paula H. Cholmondeley | Director | 30,627 |
| Brenda Cooperstone | Director | – |
| Mette Kirstine Agger | Director | – |
| Tolga Tanguler | Director | – |
| Reinaldo M. Diaz | Director | – |
| Steven Altschuler | Director | – |
| Hauwermeiren Timothy Van | Director | – |
| Laura Sepp-Lorenzino | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 59 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 29, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 6, 2023 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 1, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |